---
schema_version: "secwatch.filing_event.v1"
accession: "0000784199-25-000069"
form_type: "8-K"
ticker: "AORT"
cik: "0000784199"
company_name: "ARTIVION, INC."
filed_at: "2025-05-05T23:59:59+00:00"
generated_at: "2026-05-22T19:51:43.099470+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Artivion Q1 revenue $99M (+2% GAAP), net loss $0.5M; raises FY 2025 guidance

## Summary
- Revenue $99.0M, up 2% GAAP (4% constant currency); net loss $(0.5)M vs net income $7.5M in Q1 2024.
- Non-GAAP net income $2.5M ($0.06 diluted); adjusted EBITDA $17.5M (+1% YoY).
- Product growth: stent grafts +14%, On-X +10%, BioGlue +7%; preservation services -23% from cyber backlog.
- FY 2025 guidance raised: revenue $423-435M (11-14% constant currency growth); adj. EBITDA $84-91M.
- Positive 30-day NEXUS data (63% MAE reduction); PMA submitted for AMDS Hybrid Prosthesis to FDA.

## SEC filing metadata
- accession: 0000784199-25-000069
- form_type: 8-K
- ticker: AORT
- cik: 0000784199
- company_name: ARTIVION, INC.
- filed_at: 2025-05-05T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/784199/000078419925000069/0000784199-25-000069-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/784199/000078419925000069/aort-20250505.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000784199-25-000069
- JSON: https://secwatch.observer/filing/0000784199-25-000069.json
- Plain text: https://secwatch.observer/filing/0000784199-25-000069.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.